Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed phosphorus-containing compounds acting as androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, hirsutism and more.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Prism Biolab Co. Ltd. to generate novel oncology drug candidates.
Pain treatment, especially non-addictive treatment for severe pain, remains a critical unmet need. Among the TRP channels, transient receptor potential cation channel subfamily M member 3 (TRMP3) is a channel expressed in somatosensory neurons, including nociceptors of rodents and humans.
Werner syndrome helicase (WRN), which plays important roles in DNA repair and maintenance of genome integrity, has been recently identified as therapeutic target for microsatellite instability (MSI)-H tumors, which have deficiencies in DNA damage repair.
Biolojic Design Ltd. announced that Nektar Therapeutics Inc. has exercised its license option to develop a program resulting from the companies’ 2021 research collaboration, established to design and test agonistic antibodies targeting tumor necrosis factor receptor type II (TNFR2).
Epidermal growth factor receptor (EGFR) is widely expressed among multiple cancer types, but patients often develop resistance to EGFR tyrosine kinase inhibitors (TKIs), which may be accompanied by increased expression of CD70.
Researchers from Biohaven Pharmaceuticals Inc. presented preclinical data for the first-in-class extracellular bispecific IgG degrader, BHV-1300, being developed for the treatment of neuroinflammatory and autoimmune disease.
Hookipa Pharma Inc. has received clearance from the U.S. FDA for its IND application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. The HB-700 program is a replicating 2-vector therapy designed to treat KRAS-mutated lung, colorectal, pancreatic and other cancers by targeting the five most prevalent KRAS mutations in these disease indications.
Shanghai De Novo Pharmatech Co. Ltd. has described antibody-immunostimulatory conjugates consisting of an antibody covalently bound to Toll-like receptor 8 (TLR8) agonists through a linker reported to be useful for the treatment of cancer.
Arbutus Biopharma Corp. has divulged programmed cell death protein 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, hepatitis B and hepatitis D infections.
RSS
